Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11119408 | 0.83 | LMNA (0.31) | SLC7A5 | |
| SCHEMBL13475076 | 0.83 | MMP1 (0.34) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL6435729 | 0.81 | LMNA (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL6435735 | 0.81 | LMNA (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL5424012 | 0.80 | SLC1A1 (0.35) | GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL6946979 | 0.79 | LMNA (0.38) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL5586415 | 0.78 | MMP1 (0.36) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL23120327 | 0.76 | MMP1 (0.40) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL23120273 | 0.76 | MMP1 (0.49) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL12332086 | 0.75 | MMP1 (0.40) | MMP1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273845-B2 | Polymeric prodrugs of vancomycin | ENZON PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7169892-B2 | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems | ASTELLAS PHARMA INC. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1591450-A1 | CONJUGATE FOR RETENTION IN BLOOD AND CANCER TISSUE-SPECIFIC DRUG DELIVERY | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-20050054026-A1 | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| US-20040136947-A1 | vancomycin-polymer conjugate; polymer is attached to both of the vancomycin amino groups | BELROSE PHARMA INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004044224-A2 | BRANCHED POLYMERIC PRODRUGS OF VANCOMYCIN | ENZON PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004044222-A2 | POLYMERIC PRODRUGS OF VANCOMYCIN | ENZON PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040136947-A1 | vancomycin-polymer conjugate; polymer is attached to both of the vancomycin amino groups | DNPEP, NPEPPS, DDOST | MMP1 2780/4885MMP2 584/4885MMP3 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.